Loading clinical trials...

ACT-MBC: A Study of Circulating Tumor Cells (CTCs) in Metastatic Breast Cancer (MBC) | Clinical Trials | Clareo Health

ACTIVE_NOT_RECRUITING

ACT-MBC: A Study of Circulating Tumor Cells (CTCs) in Metastatic Breast Cancer (MBC)

ACT-MBC: A Prospective Observational Impact Study of Circulating Tumor Cells (CTCs) in Metastatic Breast Cancer

NCT05662345•Menarini Silicon Biosystems, INC

Summary

ACT-MBC prospectively assesses the impact of CTCs on treatment decisions, response assessment and prognosis in MBC patients.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Invasive breast cancer with radiographic and/or clinical evidence of advanced metastatic or unresectable disease
•2. ER+/HER2- patients prior to starting 2nd line therapy or beyond OR ER/Progesterone Receptor (PR)/HER2-negative (Triple Negative) patients prior to starting any line of therapy
•3. Measurable and/or non-measurable disease is allowed
•4. Male or female breast cancer is allowed
•5. Age \> 18 years
•6. Willingness to provide mandatory blood specimens
•7. Willing to return to enrolling institution for follow up imaging at least once

Exclusion Criteria

•1. Life expectancy of ≤ 6 months
•2. Inability to provide blood samples based on the judgment of the treating provider

Locations (4)

Mayo Clinic Health System Albert Lea

Albert Lea, Minnesota, United States

Mayo Clinic Health System Mankato

Mankato, Minnesota, United States

Mayo Clinic

Rochester, Minnesota, United States

MCHS Eau Claire

Eau Claire, Wisconsin, United States

Key Dates

Start Date

December 12, 2022

Primary Completion Date

November 14, 2025

Completion Date

October 1, 2026

Last Updated

March 17, 2026

Enrollment

ESTIMATED participants

Conditions

Metastatic Breast Cancer

Interventions

CellSearch Circulating Tumor Cells

DIAGNOSTIC_TEST

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

NCT06625775

Solid Tumor, AdultMetastatic Breast Cancer+9 more

View study

RECRUITINGPHASE2

Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer

NCT06649331

Advanced Breast CancerMetastatic Breast Cancer+3 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 17, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

ACT-MBC: A Study of Circulating Tumor Cells (CTCs) in Metastatic Breast Cancer (MBC)

Inclusion Criteria

Exclusion Criteria

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer

Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)

A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer

A Study Comparing Cancer Imaging Approaches in People With Lobular Breast Cancer

A Study of Surgery and Radiotherapy in People With Breast Cancer